Showing 2251-2260 of 2657 results for "".
- Nicox European Patent Seals Zerviate Major Market Coverage to 2030https://modernod.com/news/nicox-european-patent-seals-zerviate-major-market-coverage-to-2030/2480545/Nicox announced that patent EP2408453, covering the company’s product Zerviate (cetirizine ophthalmic solution) 0.24%, has been issued by the European Patent Office (EPO). The patent covers the formulation of Zerviate which is commercialized in the US by exclusive US licensee
- EyeQue Launches MyReaderNumber App: Personalized Results for Reading and Computer Glasseshttps://modernod.com/news/eyeque-launches-myreadernumber-app-personalized-results-for-reading-and-computer-glasses/2480543/EyeQue introduced a first-of-its-kind smartphone app called MyReaderNumber that offers AR technology vision testing for presbyopia. EyeQue’s new AR-powered MyReaderNumber app delivers personalized measurements for both near reading distance and mid-distance (computer us
- US Authorizes Pfizer's COVID-19 Pill Paxlovidhttps://modernod.com/news/us-authorizes-pfizers-covid-19-pill-paxlovid/2480535/The FDA on Wednesday authorised Pfizer's Paxlovid (nirmatrelvir) for emergency use, making it the first oral antiviral for COVID-19 cleared in the US. The agency said the prescription treatment, which is co-packaged with ritonavir, is indicated for patients aged 12 and older with mild-to
- Glaukos Announces Retirement of William J. Link, PhD, as Chairman of the Board; and Election of Thomas W. Burns as New Chairmanhttps://modernod.com/news/glaukos-announces-retirement-of-william-j-link-phd-as-chairman-of-the-board-and-election-of-thomas-w-burns-as-new-chairman/2480530/Glaukos announced that William J. Link, PhD, will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos’ Board and has served as Chairman since June 2001. In connection with Dr. Link’s retirement, the Board has appointed Thomas W. Burns, Glaukos&rs
- Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-positive-safety-results-from-oasis-phase-12a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2480529/Clearside Biomedical announced positive safety results from OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector. OASIS is evaluating CLS-AX for the treatment o
- Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucomahttps://modernod.com/news/nicox-announces-first-patient-in-china-screened-in-the-ongoing-ncx-470-denali-phase-3-trial-in-glaucoma/2480521/Nicox SA announced that the first patient has been screened in China in the ongoing Denali phase 3 clinical trial, opening the way for new drug application (NDA) submissions in both the United States and China for NCX 470, Nicox’s lead clinical product candidate in glaucoma. Denali, wh
- Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunologyhttps://modernod.com/news/aramis-biosciences-launches-to-address-unmet-needs-in-ocular-immunology/2480514/Aramis Biosciences announced its launch and the completion of a $10.5 million Series A financing led by Safar Partners with a strategic investment from a global leader in ophthalmic pharmaceuticals. Proceeds from the financing will be used to advance the company’s pipeline, including i
- Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of Brimochol for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-announces-positive-topline-clinical-data-from-phase-2-vivid-study-of-brimochol-for-the-treatment-of-presbyopia/2480481/Visus Therapeutics reported positive topline results from VIVID, the company’s phase 2 study of three novel topical ophthalmic formulations under investigation for the treatment of presbyopia. All three investigational candidates studied in VIVID achieved the endpoint of 3 lines of improvem
- Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europehttps://modernod.com/news/nicox-is-granted-patent-for-blepharitis-product-candidate-ncx-4251-in-europe/2480459/Nicox SA announced that patent EP 3,769,753, expiring in 2040 and covering the company’s product candidate in development for blepharitis, NCX 4251, has been issued by the European Patent Office (EPO). The patent covers ophthalmic suspensions comprising a specific form of fluticas
- EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategyhttps://modernod.com/news/eyegate-is-now-kiora-pharmaceuticals-provides-update-on-companys-sharpened-clinical-development-strategy/2480411/Kiora Pharmaceuticals is the new name of EyeGate Pharmaceuticals. The new brand reflects the company’s aim to not only treat common eye conditions, but to develop a small molecule therapy for retinitis pigmentosa. Kiora will trade on the Nasdaq